Cargando…

Empagliflozin decreases remnant‐like particle cholesterol in type 2 diabetes patients with insulin resistance

AIMS/INTRODUCTION: Remnant lipoproteins are thought to be atherogenic. Remnant‐like particle cholesterol (RLP‐C), which reflects the levels of various kinds of remnant lipoproteins in the blood, has a significant correlation with insulin resistance. MATERIALS AND METHODS: In the present study, we me...

Descripción completa

Detalles Bibliográficos
Autor principal:	Hattori, Sachiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6031503/ https://www.ncbi.nlm.nih.gov/pubmed/29193767 http://dx.doi.org/10.1111/jdi.12781

Ejemplares similares

Anti-inflammatory effects of empagliflozin in patients with type 2 diabetes and insulin resistance
por: Hattori, Sachiko
Publicado: (2018)

Omarigliptin decreases inflammation and insulin resistance in a pleiotropic manner in patients with type 2 diabetes
por: Hattori, Sachiko
Publicado: (2020)

Cholesterol remnants and triglycerides are associated with decreased myocardial function in patients with type 2 diabetes
por: Jørgensen, Peter Godsk, et al.
Publicado: (2016)

Association between Remnant-Like Particle Cholesterol and Gamma-Glutamyltransferase in Dyslipidemic Patients
por: Kotani, Kazuhiko, et al.
Publicado: (2013)

Correlation between estimated plasma remnant-like particle cholesterol and vegetable fat intake in Uku town, Japan
por: Adachi, Hisashi, et al.
Publicado: (2021)

High remnant cholesterol level is relevant to diabetic retinopathy in type 2 diabetes mellitus
por: Shan, Yongyan, et al.
Publicado: (2022)

Effects of risperidone and olanzapine on remnant-like lipoprotein particle cholesterol (RLP-C) in schizophrenic patients
por: Nagamine, Takahiko
Publicado: (2008)

Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin
por: Ahmann, Andrew
Publicado: (2015)

The role of remnant cholesterol beyond low-density lipoprotein cholesterol in diabetes mellitus
por: Hu, Xiangming, et al.
Publicado: (2022)

Associations Between Bioavailable Vitamin D and Remnant Cholesterol in Patients With Type 2 Diabetes Mellitus
por: Turkes, Gulsum Feyza, et al.
Publicado: (2021)

Remnant-Like Particle Cholesterol and the Risk of Major Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis
por: Yang, Jie, et al.
Publicado: (2022)

Empagliflozin in type 1 diabetes
por: Mathieu, Chantal, et al.
Publicado: (2019)

Remnant cholesterol and the risk of cardiovascular disease in type 2 diabetes: a nationwide longitudinal cohort study
por: Huh, Ji Hye, et al.
Publicado: (2022)

Remnant cholesterol is independently asssociated with an increased risk of peripheral artery disease in type 2 diabetic patients
por: Song, Yi, et al.
Publicado: (2023)

Significance of Circulating Remnant Lipoprotein Cholesterol Levels Measured by Homogeneous Assay in Patients with Type 2 Diabetes
por: Matsushima-Nagata, Kazumi, et al.
Publicado: (2023)

Association of remnant cholesterol with hypertension, type 2 diabetes, and their coexistence: the mediating role of inflammation-related indicators
por: Wu, Yuxuan, et al.
Publicado: (2023)

The Effects of Calculated Remnant-Like Particle Cholesterol on Incident Cardiovascular Disease: Insights from a General Chinese Population
por: Chen, Yanli, et al.
Publicado: (2021)

Increased estimated remnant-like particle cholesterol is associated with impaired coronary collateralization in patients with coronary chronic total occlusions
por: Gao, Ang, et al.
Publicado: (2022)

Remnant cholesterol is associated with cardiovascular mortality
por: Zhang, Kerui, et al.
Publicado: (2022)

Contribution of Remnant Cholesterol to Coronary Atherosclerosis
por: Ohmura, Hirotoshi
Publicado: (2022)

The longitudinal association of remnant cholesterol with cardiovascular outcomes in patients with diabetes and pre-diabetes
por: Cao, Ye-Xuan, et al.
Publicado: (2020)

Impact of Serum Retinol-Binding Protein 4 Levels on Regulation of Remnant-Like Particles Triglyceride in Type 2 Diabetes Mellitus
por: Yamaaki, Naoto, et al.
Publicado: (2013)

Combined Effect of Small Dense Low-Density Lipoprotein Cholesterol (sdLDL-C) and Remnant-Like Particle Cholesterol (RLP-C) on Low-Grade Inflammation
por: Izumida, Toshihide, et al.
Publicado: (2020)

Empagliflozin in the treatment of type 2 diabetes: evidence to date
por: Shubrook, Jay H, et al.
Publicado: (2015)

Myopathy secondary to empagliflozin therapy in type 2 diabetes
por: Gao, Frank, et al.
Publicado: (2020)

Prognostic impact of estimated remnant-like particle cholesterol in patients with differing glycometabolic status: an observational cohort study from China
por: Zhao, Qi, et al.
Publicado: (2020)

Empagliflozin therapy and insulin resistance-associated disorders: effects and promises beyond a diabetic state
por: Papaetis, Georgios S.
Publicado: (2021)

Effects of liraglutide and empagliflozin added to insulin therapy in patients with type 2 diabetes: A randomized controlled study
por: Nakaguchi, Hirotatsu, et al.
Publicado: (2020)

Effect of empagliflozin versus linagliptin on body composition in Asian patients with type 2 diabetes treated with premixed insulin
por: Zeng, Yi-Hong, et al.
Publicado: (2022)

Empagliflozin-Induced Euglycemic Diabetic Ketoacidosis in Type 2 Diabetes Mellitus
por: Albugami, Muneerah M., et al.
Publicado: (2020)

The non-linear link between remnant cholesterol and diabetic retinopathy: a cross-sectional study in patients with type 2 diabetic mellitus
por: Pan, Wushan, et al.
Publicado: (2022)

Major Pathophysiology in Prediabetes and Type 2 Diabetes: Decreased Insulin in Lean and Insulin Resistance in Obese
por: Kabadi, Udaya M.
Publicado: (2017)

Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes
por: Munir, Kashif M, et al.
Publicado: (2016)

The role of empagliflozin in the management of type 2 diabetes by patient profile
por: Hedrington, Maka S, et al.
Publicado: (2015)

Cardiovascular Outcomes with Empagliflozin – News for Type 2 Diabetes Therapy
por: Gallwitz, Baptist
Publicado: (2016)

Options for empagliflozin in combination therapy in type 2 diabetes mellitus
por: Hershon, Kenneth S
Publicado: (2016)

Insulin resistance and decreased spexin in Indian Patients with Type 2 Diabetes Mellitus
por: Tejaswi, G, et al.
Publicado: (2021)

Hypercholesterolemia and insulin resistance associated with ovarian remnant syndrome in a diabetic dog: case report
por: Moosavian, Hamidreza, et al.
Publicado: (2022)

High Remnant Cholesterol Level Potentiates the Development of Hypertension
por: Chen, Ming-Ming, et al.
Publicado: (2022)

Cholesterol Remnants, Triglyceride-Rich Lipoproteins and Cardiovascular Risk
por: Baratta, Francesco, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2lkhusi606r5nj0n4nt5js9hqj